LIFESTANCE HEALTH GROUP INC (LFST) Forecast, Price Target & Analyst Ratings

NASDAQ:LFST • US53228F1012

6.47 USD

-0.11 (-1.67%)

Last: Mar 18, 2026, 11:35 AM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LIFESTANCE HEALTH GROUP INC (LFST).

Consensus Price Target

Price Target

$9.07

+ 40.13% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: N/A
Period: Q1 / 2026
EPS Estimate: $0.01
Revenue Estimate: 395.11M

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

82.35%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$9.07

Upside

+ 40.13%

From current price of $6.47 to mean target of $9.07, Based on 17 analyst forecasts

Low

$7.07

Median

$8.67

High

$11.55

Price Target Revisions

1 Month

1.27%

3 Months

3.70%

Price Target Summary

17 Wall Street analysts provided a forecast for the next 12 months for LFST. The average price target is 9.07 USD. This implies a price increase of 40.13% is expected in the next year compared to the current price of 6.47.

The average price target has been revised upward by 3.7% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

82.35%

LFST was analyzed by 17 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about LFST.

In the previous month the buy percentage consensus was at a similar level.

LFST was analyzed by 17 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-03-06	Barclays	Maintains	Overweight -> Overweight
2026-02-26	UBS	Maintains	Buy -> Buy
2026-02-26	Keybanc	Maintains	Overweight -> Overweight
2026-02-26	Canaccord Genuity	Maintains	Buy -> Buy
2026-02-02	BTIG	Maintains	Buy -> Buy
2025-12-12	BTIG	Maintains	Buy -> Buy
2025-12-09	Barclays	Initiate	Overweight
2025-11-13	BMO Capital	Initiate	Outperform
2025-11-07	UBS	Maintains	Buy -> Buy
2025-11-06	BTIG	Maintains	Buy -> Buy
2025-08-08	UBS	Maintains	Buy -> Buy
2025-05-27	UBS	Upgrade	Neutral -> Buy
2025-04-08	Keybanc	Initiate	Overweight
2025-04-03	Canaccord Genuity	Initiate	Buy
2024-12-16	Goldman Sachs	Upgrade	Neutral -> Buy
2024-11-11	Barclays	Maintains	Underweight -> Underweight
2024-08-15	UBS	Maintains	Neutral -> Neutral
2024-08-09	Barclays	Maintains	Underweight -> Underweight
2024-04-22	Morgan Stanley	Reiterate	Overweight -> Overweight
2024-03-06	Jefferies	Maintains	Buy -> Buy
2024-03-04	Goldman Sachs	Maintains	Neutral -> Neutral
2024-02-29	Barclays	Maintains	Underweight -> Underweight
2023-11-22	Goldman Sachs	Maintains	Neutral -> Neutral
2023-11-17	JP Morgan	Maintains	Neutral -> Neutral
2023-08-10	JP Morgan	Maintains	Neutral -> Neutral

Next Earnings Forecast Details

Next Earnings Details

Release Date: N/A
Period: Q1 / 2026
EPS Estimate: $0.01
Revenue Estimate: 395.11M
Revenue Q2Q: 18.66%
EPS Q2Q: N/A
Number of Analysts: 11

Next Earnings Revisions

Revenue (1 Month)

1.80%

Revenue (3 Months)

1.64%

EPS (1 Month)

100.00%

EPS (3 Months)

100.00%

Next Earnings Summary

The next earnings revenue estimate has been revised upward by 1.64% in the past 3 months.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2023	2024	2025	2026	2027	2028
Revenue YoY % growth	1.056B 22.82%	1.251B 18.50%	1.424B 13.85%	1.669B 17.18%	1.904B 14.08%	2.171B 14.02%
EBITDA YoY % growth	-106.911M 21.91%	39.509M 136.96%	78.901M 99.70%	197.74M 150.62%	242.94M 22.86%	295.54M 21.65%
EBIT YoY % growth	-187.348M 9.10%	-31.441M 83.22%	24.148M 176.80%	37.983M 57.29%	80.724M 112.53%	86.176M 6.75%
Operating Margin	-17.75%	-2.51%	1.70%	2.28%	4.24%	3.97%
EPS YoY % growth	-0.51 16.39%	-0.16 68.63%	0.02 112.50%	0.06 189.02%	0.16 184.86%	0.26 56.93%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26	Q1 / 27	Q2 / 27	Q3 / 27	Q4 / 27
EPS Q2Q % growth	0.01	0.02 253.00%	0.02	0.02 -43.32%	0.05 400.00%	0.06 300.00%	0.06 300.00%	0.08 379.90%
Revenue Q2Q % growth	395.11M 18.66%	409.55M 18.60%	423M 16.27%	435.44M 13.93%	451.48M 14.27%	471.96M 15.24%	494.05M 16.80%	496.42M 14.00%
EBITDA Q2Q % growth	43.237M 181.49%	46.763M 88.47%	47.809M -1.89%	48.749M -33.07%	49.286M 13.99%	56.233M 20.25%	57.803M 20.90%	61.776M 26.72%
EBIT Q2Q % growth	10.246M 538.78%	13.492M 557.36%	8.709M 17.53%	8.224M -54.52%	N/A	N/A	N/A	N/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

134.65%

EPS Next 5 Year

N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

14.45%

Revenue Next 5 Year

N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

208.48%

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

LIFESTANCE HEALTH GROUP INC / LFST Forecast FAQ

Can you provide the average price target for LIFESTANCE HEALTH GROUP INC stock?

17 analysts have analysed LFST and the average price target is 9.07 USD. This implies a price increase of 40.13% is expected in the next year compared to the current price of 6.47.

What are the consensus estimates for LFST stock next earnings?

The consensus EPS estimate for the next earnings of LIFESTANCE HEALTH GROUP INC (LFST) is 0.01 USD and the consensus revenue estimate is 395.11M USD.

What is the expected long term growth rate for LIFESTANCE HEALTH GROUP INC (LFST)?

The expected long term growth rate for LIFESTANCE HEALTH GROUP INC (LFST) is 14.45%.

Analyst forecast overview

Forecast Snapshot